Trastuzumab deruxtecan in HER2-low metastatic breast cancer treatment
Trastuzumab deruxtecan is an antibody-drug conjugate which has shown effectiveness in patients with HER2-low disease. In this MEDtalk Giuseppe Curigliano’s presents results from a phase three trial (DESTINY-Breast04) investigating the effectiveness and safety profile of trastuzumab deruxtecan which might should be considered in treatment algorithms for these patients.